Advanced Melanoma In Remission After Infusing Patient With Clones Of His Own Killer T Cells
Added: 19 июня 2008
Last relative articles:
- O'Keefe Receives Gruber Neuroscience Prize For Discovery Of Place Cells And Their Role In Cognition
- Seminar Focuses On Quality And Safety In Nursing Education, Illinois, USA
- UO Team's Findings Could Pave Way For Synthetic Compounds Useful In Drug Discovery And Materials Science
- Former President George Bush And Barbara Bush Lead C-Change Initiative To Unify Public Education Messages On Cancer Prevention And Early Detection
- Published Study Reveals Next Pharmaceuticals' Flavoxine trade; Reduces Multiple Heart Health Risk Factors Including High Cholesterol
- AquaSlim Helps You Get The Summer You Deserve -- Drink Thin With New AquaSlim
- Market America Announces Plans To Launch Vitamins For Children With Autism
- Wedensky Modulation Identifies Sudden Cardiac Arrest Risk In Patients
- VitalCare's Patient Of The Month Program Launch
- A New Approach To Epilepsy Treatment Takes Its First Steps
Comments: [0] / Post comment:
02 Dec 2008 13:19:01
First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using ... - WELT ONLINE
First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using ... WELT ONLINE, Germany - The paper concluded: "This first human trial, to our knowledge, of gene transfer utilizing in vivo DNA electroporation in metastatic melanoma showed that it ... Inovio Biomedical Says Final Results of Phase I Study Show Safe ...
02 Dec 2008 07:00:42
Later On: Non-melanoma skin cancer can forecast others - Winston-Salem Journal
Later On: Non- melanoma skin cancer can forecast others Winston-Salem Journal, NC - This study: It analyzed data on 19174 people age 25 and older, 769 of whom had received a diagnosis of non- melanoma skin cancer (either basal cell or ...
02 Dec 2008 02:37:31
Patients presenting to skin clinic earlier than to other hospitals - Irish Times
Patients presenting to skin clinic earlier than to other hospitals Irish Times, Ireland - Dr Bourke said the melanoma clinic, which was established at the South Infirmary Victoria in 2003, carried out a major comparative study of trends in ...
02 Dec 2008 01:29:21
Reflectance Confocal Microscopy for Melanoma and Melanocytic ... - Medscape
Reflectance Confocal Microscopy for Melanoma and Melanocytic ... Medscape - Disclosure: Charles P. Vega, MD, FAAFP, has disclosed that he has served as an advisor or consultant to Novartis, Inc. Disclosure: Elisa Manzotti has ...
01 Dec 2008 23:17:32
Spot the deadly dot - MyTown Bay of Plenty
Spot the deadly dot MyTown Bay of Plenty, New Zealand - About a month ago, the 31-year-old was diagnosed with melanoma , after a freckle on his lower thigh changed colour a few months after he returned to New ...
01 Dec 2008 20:35:48
Banc of America skeptical on Synta drug - Forbes
Banc of America skeptical on Synta drug Forbes, NY - He has doubts about the company's developing cancer drug elesclomol and whether it will make it past a late-stage study of patients with metastatic melanoma ...
01 Dec 2008 15:13:00
Marshall Edwards, Inc. Files IND Application for Triphendiol - MarketWatch
Marshall Edwards, Inc. Files IND Application for Triphendiol MarketWatch - ... for use in conjunction with standard chemotoxic anti-cancer drugs for the treatment of late stage pancreatic cancer, cholangiocarcinoma, and melanoma . ...
01 Dec 2008 06:51:35
Understanding Why Melanoma Survives - Ivanhoe
Understanding Why Melanoma Survives Ivanhoe, FL - Their findings could help doctors design new strategies to prevent malignant melanoma . The process of tanning involves synthesis of the pigment melanin by ...
30 Nov 2008 18:00:29
Melanoma cases likely to decline - Stuff.co.nz
Melanoma cases likely to decline Stuff.co.nz, New Zealand - ... caused by clear skies and bright sunshine kill between 250 and 300 Kiwis a year, giving New Zealand the highest death rate from melanoma in the world. ... Warning over summer sun
25 Nov 2008 14:45:36
Enrollment in Provectus' Phase 2 Melanoma Clinical Trial Reaches ... - MarketWatch
Enrollment in Provectus' Phase 2 Melanoma Clinical Trial Reaches ... MarketWatch - a development-stage oncology and dermatology biopharmaceutical company, announced today that the first fifty percent (40 of 80) of melanoma subjects have ... Enrollment in Provectus' Phase 2 Melanoma Clinical Trial Reaches ...